CF Acquisition Corp. V (CFV) Peer Comparison
$8.10
$-0.55
(-6.36%)
As on 26-Jan-2022 09:30EDT
Market cap
$276 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Edit
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
276 | 5,305 | 3,392 | 778 | 449 |
Revenue ($ Mln) |
-- | 440 | 2,883 | -- | 330 |
Net Profit ($ Mln) |
-3.32 | -1,435.01 | -118.30 | -134.20 | 100.20 |
Net Margin (%) |
-74.44 | -325.91 | -4.10 | -- | 30.33 |
RoE (%) |
-- | -- | -- | -40.17 | 30.44 |
Price to Earnings |
-- | -- | -- | -- | 4.68 |
Price-To-Book |
1.27 | -- | 1.35 | -- | 1.31 |
Income Statement ($ Mln)
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 60.32 | 1,912.90 | 64.89 | 846.66 |
|
Cost of Revenue
|
0.00 | 50.93 | 1,220.00 | -- | 844.32 |
|
Gross Profit
|
-- | 9.39 | 692.90 | 64.89 | 2.34 |
|
Operating Expenses
|
3.27 | 21.60 | 597.00 | 120.07 | 134.44 |
|
Operating Profit (EBIT)
|
-3.35 | -6.33 | 95.90 | -55.18 | -132.10 |
|
Other Income
|
4.46 | -- | -- | 2.46 | 64.80 |
|
Profit before Tax
|
-3.32 | -12.21 | -17.90 | -55.36 | -132.10 |
|
Provision for Tax
|
0.00 | -4.97 | 17.30 | -- | -36.61 |
|
Profit after Tax (Net Income)
|
-3.32 | -12.21 | -19.60 | -55.36 | -96.45 |
|
Minority Interest
|
0.00 | -- | -- | -- | 21.85 |
|
Consolidated Profit
|
-3.32 | -22.68 | -- | -55.36 | -96.45 |
Liabilities ($ Mln)
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-13.19 | 133.70 | -236.90 | 385.61 | 395.75 |
|
Minority Interest
|
0.00 | -- | -- | -- | 21.85 |
|
Non-Current Liabilities
|
10.33 | 22.23 | 2,346.70 | 81.73 | 160.35 |
|
Current Liabilities
|
3.53 | 69.65 | 1,360.30 | 51.56 | 0.01 |
|
Total Liabilities
|
0.16 | 225.58 | 3,690.80 | 518.90 | 2,848.94 |
Assets ($ Mln)
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
250.16 | 154.66 | 2,762.50 | 77.33 | 1,076.62 |
|
Current Assets
|
0.51 | 70.92 | 928.30 | 441.57 | 1.39 |
|
Total Assets
|
0.16 | 225.58 | 3,690.80 | 518.90 | 2,848.94 |
|
Total Debt*
|
0.00 | 40.29 | 2,353.70 | 63.92 | 160.35 |
|
Net Current Assets
|
-3.02 | 1.27 | -- | 390.01 | -- |
Cashflow ($ Mln)
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-- | -23.77 | -232.40 | -81.14 | -10.47 |
|
Cash Flow from Investing Activities
|
-- | -15.14 | -0.30 | -282.36 | 36.57 |
|
Cash from Financing Activities
|
0.03 | 40.72 | 365.00 | 356.62 | -11.65 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -6.88 | 14.44 |
Ratios
Profitability Ratios
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-- | -7.69 | -- | -20.62 | -15.43 |
|
ROE (%)
|
-- | -9.06 | -- | -24.51 | -20.98 |
|
ROA (%)
|
-2.61 | -6.30 | -- | -15.21 | -3.63 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-74.44 | -20.24 | -1.02 | -82.19 | -10.58 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.01 | -- | 0.80 | 0.03 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-- | -2.38 | -- | 0.24 | -222.89 |
|
EPS Growth (%)
|
-- | -- | -- | 0.14 | -2.22 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -- | -- | -73.83 | -2.54 |
|
Price / Book Value
|
-- | -- | -- | 10.60 | 0.62 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | -- | -- | -71.54 | 6.94 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.30 | -9.94 | 0.17 | 0.41 |
|
Short term debt to equity ratio
|
0.00 | 0.14 | -1.65 | 0.02 | 0.01 |
|
Current Ratio
|
0.14 | 1.02 | 0.68 | 8.56 | 126.46 |
|
Quick Ratio
|
0.14 | 0.18 | -- | -- | 144,508.36 |
|
Interest Coverage
|
-- | -1.75 | 0.84 | -19.94 | -12.79 |
Operating Efficiency Ratios
| CF Acquisition Corp. V (CFV) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 1.84 | 23.89 | 0.26 | 107.30 |
|
Asset Turnover
|
0.00 | 0.31 | -- | 0.18 | 0.32 |
|
Receivable days
|
-- | 4.22 | 395.47 | 0.97 | 333.30 |
|
Inventory Days
|
-- | 418.19 | -- | -- | -446.29 |
|
Payable days
|
-- | 37.87 | 46.08 | -- | 124.92 |
|
Cash Conversion Cycle
|
-- | 384.55 | -- | -- | -237.91 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
